Join us to explore the latest advancements in pharmacogenomic (PGx) analysis with our newly launched Infinium microarrays and DRAGEN Array software. The Infinium Global Clinical Research Array with ...

Agilent’s Microarray Hybridization Oven was designed for optimal hybridization performance and ultimately, consistently reliable data. With advanced features including variable and adjustable ...

Microarray analysis identifies more chromosome abnormalities than traditional karyotyping in prenatal testing. Microarrays will also identify findings of unclear clinical significance that should ...

A RECENT analysis of the IDEAL clinical trial highlights a breakthrough for early-stage breast cancer. The study shows that a 70-gene expression risk-of-recurrence assay can guide decisions about ...

SANTA CLARA, Calif., and SINGAPORE, July 20, 2011 - Agilent Technologies Inc. (NYSE: A) today announced that Molecular Genomics is the newest Agilent Certified Service Provider offering microarray ...

Rick Baehner, Chief Medical Officer, Precision Oncology at Exact Sciences. “For 20 years, the Oncotype DX test has led the way in personalized treatment planning, and the new findings presented ...

New data supports the value of the Oncotype DX Breast Recurrence Score® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally Exact ...

New data supports the value of the Oncotype DX Breast Recurrence Score ® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally MADISON, Wis.-- ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the ...